The Hidden Rivalry: How Psoriasis and Atopic Dermatitis Play Immunological Tug-of-War – And Why Your Treatments Might Trigger the Switch!
Imagine two common skin conditions that seem worlds apart – psoriasis with its scaly, red patches, and atopic dermatitis (often called eczema) with its itchy, inflamed rashes. But beneath the surface, these aren't just random annoyances; they're locked in a fascinating immunological battle. Psoriasis thrives on a Th17-driven immune storm, while atopic dermatitis is fueled by Th2 overactivity. And here's the kicker: targeting one can unexpectedly unleash the other, turning your treatment into an unexpected plot twist. Dermatologists remain on high alert for these systemic risks, especially with the rise of biologic therapies that promise dramatic improvements in quality of life for millions.
But here's where it gets controversial – could these seemingly opposite diseases actually share more in common than we think? In this deep dive, we'll unpack their mechanisms, explore real-world cases, and uncover why some patients see their symptoms flip like a switch. And this is the part most people miss: the latest advances in sequencing tech are rewriting our understanding, hinting at broader implications for personalized medicine.
Diving into Contrasting Immunopathogenesis
To grasp why psoriasis and atopic dermatitis (AD) clash so dramatically, let's break down their immune underpinnings. Both are chronic inflammatory skin disorders rooted in immune dysregulation, but their pathways couldn't be more different. Psoriasis leans heavily on Th17 cell hyperactivity, while AD is dominated by Th2 imbalances. This divergence shapes everything from symptoms to treatment approaches, and it's grounded in both genetic and environmental factors – think of it as two sides of the same immune coin.
Unraveling Psoriasis's Immune Drama
Psoriasis isn't just a surface issue; it's a full-blown immune rebellion. At its core, the disease involves excessive keratinocyte (skin cell) proliferation and abnormal maturation, often triggered by a mix of innate and adaptive immune responses. Genetics play a starring role here, influencing how the body responds to stress or infection. For beginners, picture this: under pressure, keratinocytes release a protective peptide called LL-37, which teams up with DNA/RNA fragments from damaged cells. This combo activates plasmacytoid dendritic cells (pDCs) via toll-like receptors (TLR9 and TLR7), sparking a cascade of type I interferons like IFN-α. These interferons then rally myeloid dendritic cells (mDCs), setting the stage for the Th17/IL-23 axis – the real powerhouse behind psoriasis's inflammation.
The IL-23/Th17 partnership is like a well-oiled machine. IL-23 acts as the master conductor, boosting Th17 cell production and function, which in turn cranks out key cytokines such as IL-17A and IL-17F. But wait – Th17 cells aren't the only IL-17 producers. Other players, including γδ T cells and type 3 innate lymphoid cells (ILC3s), jump in early, responding swiftly to IL-23 and amplifying the response. These cells are like the first responders in a fire, making the inflammation rapid and intense. Guided by homing receptors like CCR6, Th17 cells follow chemotactic signals (like CCL20) to infiltrate the skin, where they escalate damage.
In psoriasis lesions, this Th17/IL-23 loop creates a self-sustaining storm. Cytokines such as IL-17A directly provoke keratinocyte overgrowth, chemokine release, and neutrophil buildup, leading to those classic thick, silvery scales. TNF-α and IFN-γ add fuel, dilating blood vessels and drawing in more immune cells. IL-22 pushes keratinocyte proliferation and differentiation to the extremes, thickening the epidermis. This vicious cycle of cytokine interplay with keratinocytes traps the condition in chronicity, with frequent flares – a hallmark of psoriasis's stubborn nature. For a real-world example, imagine a patient whose psoriasis plaques persist despite creams; it's this loop keeping the fire alive.
Peeling Back Atopic Dermatitis's Layers
Atopic dermatitis, or eczema, flips the script with its Th2-centric immune profile, especially acute or early-onset cases, and even more so in Asian populations. Unlike psoriasis, AD revolves around a cycle of skin barrier breakdown and immune overdrive. Key players include alarm signals from stressed keratinocytes, such as thymic stromal lymphopoietin (TSLP), IL-25, and IL-33. These trigger type 2 innate lymphoid cells (ILC2s) to flood the area with IL-5, IL-9, and IL-13. Dendritic cells chime in, nudging naive T cells toward Th2 differentiation.
This Th2 crew unleashes a barrage: IL-4, IL-5, IL-9, IL-13, and IL-31, spiking eosinophils, IgE antibodies, and widespread itch. IL-4 and IL-13 are the dynamic duo here – IL-4 primes T cells for Th2 fate, while IL-13 dismantles the skin barrier by dialing down filaggrin (a key protective protein). Together, they forge a self-reinforcing loop: IL-4 sustains Th2 expansion, IL-13 invites allergens through weakened defenses, perpetuating the cycle. IL-31 adds a neural twist, activating itch pathways in sensory neurons – think relentless scratching that worsens barrier damage, creating a scratch-itch-barrier-breakdown vortex.
Notably, AD's immune landscape can shift, incorporating Th1, Th17, or Th22 elements, with Th1 prominent in chronic cases and Th17 in Asian folks. This variability underscores AD's complexity, making it responsive to different triggers like infections or allergens.
The Antagonistic Mechanism: Why These Diseases Can't Coexist Easily
Psoriasis and AD aren't just different; they're actively antagonistic. Their immune pathways – Th1/Th17 versus Th2 – form a delicate balance, where boosting one suppresses the other. Clinical and lab evidence shows this mutual inhibition, explaining why patients rarely have both conditions simultaneously.
The Th1/Th17 and Th2 Tug-of-War
In this immune seesaw, IFN-γ (a Th1 cytokine) quells Th2 activity at the genetic level, blocking GATA3 (a Th2 master switch) and suppressing Th2 cytokines. IFN-γ also boosts Th1/Th17 strength and shapes a Th2-hostile environment via macrophages and dendritic cells. On the flip side, IL-4 and IL-13 (Th2 staples) inhibit Th17 differentiation by activating STAT6 and downregulating RORγt, preventing naive T cells from going Th17. Some research suggests IL-4/IL-13 might indirectly dampen IL-17's effects on keratinocytes by altering gene expression like FLG, though this needs more proof. Even antigen-driven IL-13 could curb Th17 paths, but its human relevance remains murky. For example, in animal models of AD or psoriasis, this inhibition is clear – blocking Th2 often unmasks Th17 dominance.
How Keratinocytes Amplify the Divide
Keratinocytes don't just sit idly; they respond differently to cytokines, exaggerating the divide. In psoriasis, IL-17/IL-22 prompts proliferation and chemokine production. In AD, IL-4/IL-13 degrades barriers, cutting filaggrin and weakening defenses. This makes keratinocytes active combatants, not bystanders, in the psoriasis-AD standoff.
Bridging the Gap: Shared Pathways
Yet, psoriasis and AD aren't entirely isolated. Shared elements like the IL-23/IL-17 axis (more in psoriasis but present in AD) and TSLP (Th2-promoting but IL-17-interacting) add nuance, especially in Asian or mixed-type patients. TSLP can modulate immune directions, and the JAK-STAT pathway integrates signals from both. IL-36, an inflammatory booster, peaks in severe AD, linking barrier issues to amplified inflammation. These overlaps suggest a dynamic interplay, not mutual exclusion, paving the way for dual-target therapies.
Clinical Insights: Rare Coexistence and Epidemiological Clues
Clinically, psoriasis and AD rarely overlap, a pattern backed by robust epidemiological data. This negative association highlights their distinct genetic predispositions, where psoriasis leans Th17 and AD toward Th2.
The Rarity of Dual Diagnosis
Doctors seldom see patients with both classic psoriasis and AD. Studies show AD patients have lower psoriasis risk, and vice versa – think of it as immune incompatibility. Genetic analyses, like Mendelian randomization, reveal AD-linked genes protect against psoriasis, suggesting innate immune blueprints steer toward one or the other.
Special Cases That Challenge the Norm
But exceptions exist: some start with childhood AD that fades, only for psoriasis to emerge later. Biologics like dupilumab (anti-IL-4Rα) for AD can spark psoriasis-like rashes by lifting Th2's brake on Th1/Th17. Rare cases show mixed lesions, pointing to disrupted immune harmony. Pediatric overlaps complicate things – severe AD can mimic psoriasis plaques, and guttate psoriasis might confuse with infected AD.
Age-Related Twists
AD peaks in infancy, psoriasis in adulthood, complicating pediatric diagnoses. These differences emphasize the need for thorough evaluations based on immune profiles.
In sum, evidence confirms psoriasis and AD's immunological opposition, with low comorbidity and protective genetics. Yet, rare switches highlight a fragile balance, crucial for treatment monitoring.
Therapeutic Twists: When Treatments Backfire
This antagonism extends to therapies. Biologics targeting one pathway can provoke the other – a paradoxical reaction demanding swift adjustments.
Th2 Blockade Unleashing Psoriasis
Blocking Th2 in AD (via IL-4/13 inhibitors) removes Th1/Th17 suppression, risking psoriasis onset. We've compiled cases where dupilumab or similar drugs induced psoriasis-like changes, sometimes needing switches.
Th17/Th1 Inhibition Triggering AD
Similarly, psoriasis treatments like anti-IL-17 or IL-23 agents can shift to Th2 dominance, causing AD-like eruptions. Our review lists these instances, including with secukinumab or ixekizumab.
JAK Inhibitors: The Balancing Act
JAK inhibitors, hitting JAK1-3 and TYK2, modulate Th1, Th2, and Th17 via STAT pathways. They restore balance in paradoxical cases, offering rapid relief without the risks of biologics. Studies show their efficacy in managing these switches, positioning them as versatile tools.
Cutting-Edge Evidence: Genomics and Transcriptomics
To decode paradoxical reactions, single-cell RNA sequencing shines. One study found psoriasis patients developing AD after biologics showed upregulated TNF and IFN-γ, not just Th2 shifts. Proteomic analyses echoed AD-like profiles. As sequencing advances, we'll uncover more molecular secrets, guiding future therapies.
Looking Ahead: Implications for Research and Care
Genetic Overlaps and Immune Subtypes
Some patients with both conditions hint at shared genetics like HLA, FLG mutations, or Th17/Th2 regulators. GWAS links these, and FLG issues in psoriasis mirror AD's barrier woes.
Novel Therapies on the Horizon
Dual-pathway drugs, like TSLP inhibitors (blocking Th2 and IL-23/IL-17) or IL-36R antagonists, promise broader relief for mixed cases. JAK inhibitors exemplify upstream regulation.
Precision Medicine's Promise
Shifting from disease labels to immune profiles – via cytokines, skin transcriptomics, or cell subsets – could tailor treatments. For AD patients resisting Th2 blockers, JAK additions might work wonders.
Why This Matters for Immunology and Practice
This research shatters the Th1/Th17 vs. Th2 binary, revealing skin immunity's plasticity and memory. Clinically, it urges vigilance for atypical rashes and personalized plans. Translating these findings could revolutionize diagnostics and therapies, moving toward cures.
What do you think about this immunological showdown between psoriasis and atopic dermatitis? Have treatments ever caused unexpected switches for you or someone you know? Is the idea of shared pathways changing how we view these conditions? Share your opinions in the comments – let's discuss!
Consent for Publication
Every contributor has given their approval for this article to be published in its entirety.
Author Contributions
Each author played a vital role in this work, from initial ideas and design to data gathering, analysis, writing, editing, and final review. All stand by the article's content and agree to its submission and publication.
Funding
Support for this research came from the Chinese Scholarship Council (grant to YZ: CSC no. 202308210137) and the Jinzhou Medical University Teacher Reserve Program (for YZ).
Disclosure
The authors report no conflicts of interest.
References
David Boothe W, Tarbox JA, Tarbox MB. Atopic dermatitis: pathophysiology. Adv Exp Med Biol. 2017;1027:21–37.
Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. doi:10.1016/S0140-6736(14)61909-7
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. doi:10.3390/ijms20061475
Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):4347. doi:10.3390/ijms20184347
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi:10.1016/S0140-6736(20)32549-6
Mrowietz U, Lauffer F, Sondermann W, Gerdes S, Sewerin P. Psoriasis as a systemic disease. Dtsch Arztebl Int. 2024. doi:10.3238/arztebl.m2024.0064
Perry M. Psoriasis: an overview. Br J Nurs. 2024;33(15):686–692. doi:10.12968/bjon.2024.0112
Lwin SM, Clements CM, Mukherjee N. Curing psoriasis. J Invest Dermatol. 2024;145(1):144. doi:10.1016/j.jid.2024.04.027
Morizane S, Yamasaki K, Mühleisen B, et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol. 2012;132(1):135–143. doi:10.1038/jid.2011.259
Honma M, Hayashi K. Psoriasis: recent progress in molecular‐targeted therapies. J Dermatol. 2021;48(6):761–777. doi:10.1111/1346-8138.15727
Sugumaran D, Yong ACH, Stanslas J. Advances in psoriasis research: from pathogenesis to therapeutics. Life Sci. 2024;355:122991. doi:10.1016/j.lfs.2024.122991
Georgescu SR, Tampa M, Caruntu C, et al. Advances in understanding the immunological pathways in psoriasis. IJMS. 2019;20(3):739. doi:10.3390/ijms20030739
Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol. 2018;54(1):102–113. doi:10.1007/s12016-018-8668-1
Singh R, Koppu S, Perche PO, Feldman SR. The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications. Int J Mol Sci. 2021;22(23):12793. doi:10.3390/ijms222312793
Krzysztofik M, Brzewski P, Kulbat A, Masajada M, Richter K, Wysocki WM. The IL-23/Th17 pathway inhibitors in the treatment of psoriasis and the risk of skin malignancies: a review. Adv Dermatol Allergol. 2024;41(6):552–559. doi:10.5114/ada.2024.143428
Petit RG, Cano A, Ortiz A et al. Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. Int J Mol Sci. 2021;22(9):4893. doi:10.3390/ijms22094983
Guo J, Zhang H, Lin W, Lu L, Su J, Chen X. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023;8(1):437. doi:10.1038/s41392-023-01655-6
Sánchez-Rodríguez G, Puig L. pathogenic role of IL-17 and therapeutic targeting of IL-17F in psoriatic arthritis and spondyloarthropathies. IJMS. 2023;24(12):10305. doi:10.3390/ijms241210305
Schinocca C, Rizzo C, Fasano S, et al. Role of the IL-23/IL-17 pathway in rheumatic diseases: an overview. Front Immunol. 2021;12:637829. doi:10.3389/fimmu.2021.637829
Bugaut H, Aractingi S. Major role of the IL17/23 axis in psoriasis supports the development of new targeted therapies. Front Immunol. 2021;12:621956. doi:10.3389/fimmu.2021.621956
Shi ZR, Mabuchi T, Riutta SJ, et al. The chemokine, CCL20, and its receptor, CCR6, in the pathogenesis and treatment of psoriasis and psoriatic arthritis. J Psoriasis Psoriatic Arthritis. 2023;8(3):107–117. doi:10.1177/24755303231159106
Meitei HT, Jadhav N, Lal G. CCR6-CCL20 axis as a therapeutic target for autoimmune diseases. Autoimmunity Rev. 2021;20(7):102846. doi:10.1016/j.autrev.2021.102846
Gómez-Melero S, Caballero-Villarraso J. CCR6 as a potential target for therapeutic antibodies for the treatment of inflammatory diseases. Antibodies. 2023;12(2):30. doi:10.3390/antib12020030
Francis L, Capon F, Smith CH, Haniffa M, Mahil SK. Inflammatory memory in psoriasis: from remission to recurrence. J Allergy Clin Immunol. 2024;154(1):42–50. doi:10.1016/j.jaci.2024.05.008
Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–255. doi:10.1146/annurev-immunol-032713-120225
Gaffen SL, Jain R, Garg AV, Cua DJ. IL-23-IL-17 immune axis: discovery, mechanistic understanding, and clinical testing. Nat Rev Immunol. 2014;14(9):585–600. doi:10.1038/nri3707
Krueger JG, Fretzin S, Suárez-Fariñas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in psoriasis. J Allergy Clin Immunol. 2012;130(1):145–54.e9. doi:10.1016/j.jaci.2012.04.024
Magliocco M, Krueger JG, Abello MV, et al. Psoriasis plaques multiple proinflammatory pathways in TNF Inhibition rapidly down-regulates.
Wolk K, Witte E, Wallace E, et al. IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36(5):1309–1323. doi:10.1002/eji.200535503
Lopez DV, Kongsbak‐Wismann M. Role of IL‐22 in homeostasis and diseases of the skin. APMIS. 2022;130(6):314–322. doi:10.1111/apm.13221
Guilloteau K, Paris I, Pedretti N, et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1α, and TNF-α recapitulates some features of psoriasis. J Immunol. 2010;184(9):5263–5270. doi:10.4049/jimmunol.0902464
Gao J, Chen F, Fang H, Mi J, Qi Q, Yang M. Daphnetin inhibits proliferation and inflammatory response in human HaCaT keratinocytes and ameliorates imiquimod-induced psoriasis-like skin lesion in mice. Biol Res. 2020;53:48. doi:10.1186/s40659-020-00316-0
Hu P, Wang M, Gao H, et al. The role of helper T cells in psoriasis. Front Immunol. 12:788940. PMID: 34975883; PMCID: PMC8714744. doi:10.3389/fimmu.2021.788940
Akhter S, Tasnim FM, Islam MN, et al. Role of Th17 and IL-17 cytokines on inflammatory and auto-immune diseases. CPD. 2023;29(26):2078–2090. doi:10.2174/1381612829666230904150808
Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339–1350. doi:10.1038/jid.2009.59
Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel, targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653. doi:10.1016/j.jaci.2017.07.004
Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405(10478):583–596. doi:10.1016/S0140-6736(24)02519-4
Afshari M, Kolackova M, Rosecka M, Čelakovská J, Krejsek J. Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches. Front Immunol. 2024;15:1361005. doi:10.3389/fimmu.2024.1361005
Chen WY, Chen SC, Hsu SY, et al. Annoying psoriasis and atopic dermatitis: a narrative review. IJMS. 2022;23(9):4898. doi:10.3390/ijms23094898
Kamata Y, Tominaga M, Takamori K. Mechanisms of itch in atopic dermatitis. Juntendo Med J. 2025;71(1):43–50. doi:10.14789/ejmj.JMJ24-0036-R
Goh MS, Yun JS, Su JC. Management of atopic dermatitis: a narrative review. Med j Aust. 2022;216(11):587–593. doi:10.5694/mja2.51560
Gomułka K, Tota M, Laska J, Gojny K, Sędek Ł. Serum concentration of IL-5 Receptor (IL-5R) and associations with disease severity in patients with chronic spontaneous urticaria (CSU) and atopic dermatitis (AD). Int J Mol Sci. 2024;25(14):7598. doi:10.3390/ijms25147598
Tsuji G, Yamamura K, Kawamura K, Kido-Nakahara M, Ito T, Nakahara T. Novel therapeutic targets for the treatment of atopic dermatitis. Biomedicines. 2023;11(5):1303. doi:10.3390/biomedicines11051303
Missaoui S, Gaadi A, Oussama K, Aadam Z, Bousfiha AA, Hali F. The primary mechanisms underlying atopic dermatitis Les principaux mécanismes sous-jacents à la dermatite atopique. Tunis Med. 2025;103:65–72.
Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol. 2023;20(5):448–474. doi:10.1038/s41423-023-00992-4
Ogulur I, Mitamura Y, Yazici D, et al. Type 2 immunity in allergic diseases. Cell Mol Immunol. 2025;22(3):211–242. doi:10.1038/s41423-025-01261-2
Szymański Ł, Cios A, Ciepielak M, Stankiewicz W. Cytokines and apoptosis in atopic dermatitis. pdia. Adv Dermatol Allergol. 2021;38(1):1–13.
Laska J, Tota M, Łacwik J, Sędek Ł, Gomułka K. IL-22 in atopic dermatitis. Cells. 2024;13(16):1398. doi:10.3390/cells13161398
Li H, Zhang Z, Zhang H, Guo Y, Yao Z. Update on the pathogenesis and therapy of atopic dermatitis. Clin Rev Allerg Immunol. 2021;61(3):324–338. doi:10.1007/s12016-021-08880-3
Torres T, Ferreira EO, Gonçalo M, Mendes-Bastos P, Selores M, Filipe P. Update on atopic dermatitis. Acta Med Port. 2019;32(9):606–613. doi:10.20344/amp.11963
Commonality of the IL-4/IL-13 pathway in atopic diseases [Internet]. 2025. Available from: https://jlylos.jlss.vip/%E5%A4%96%E5%88%8A%E5%85%A8%E6%96%87%2F2017%2F1744-666X%2F13%2F5%2F31037238.pdf?X-Tos-Algorithm=TOS4-HMAC-SHA256&X-Tos-Credential=AKLTNGZhYzU5ODhjOGY0NGNhMjhkMDYyY2UzOTM1Y2NhYTg%2F20251008%2Fcn-guangzhou%2Ftos%2Frequest&X-Tos-Expires=3600&X-Tos-Date=20251008T115914Z&X-Tos-Signature=188b6ec7dc92a9ace28a8c16b311458bbca6f6f9f498c414ae565dc69ca21aaa&X-Tos-SignedHeaders=host (https://jlylos.jlss.vip/%25E5%25A4%2596%25E5%2588%258A%25E5%2585%25A8%25E6%2596%87%252F2017%252F1744-666X%252F13%252F5%252F31037238.pdf?X-Tos-Algorithm=TOS4-HMAC-SHA256%26X-Tos-Credential=AKLTNGZhYzU5ODhjOGY0NGNhMjhkMDYyY2UzOTM1Y2NhYTg%252F20251008%252Fcn-guangzhou%252Ftos%2Frequest%26X-Tos-Expires=3600%26X-Tos-Date=20251008T115914Z%26X-Tos-Signature=188b6ec7dc92a9ace28a8c16b311458bbca6f6f9f498c414ae565dc69ca21aaa%26X-Tos-SignedHeaders=host) . Accessed December 25, 2025.
Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol. 2010;28:445–489. doi:10.1146/annurev-immunol-030409-101212
Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2(3):e24137. doi:10.4161/jkst.24137
Beck LA, Graham NM, Ming JE, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. n Engl J Med. 2014;(2):130–139. doi:10.1056/NEJMoa1314768
Santamaria-Babi L. Atopic dermatitis pathogenesis: lessons from immunology. Dermatol Pract Concept. 2022;12(1):e2022152. doi:10.5826/dpc.1201a152
Schuler CF, Billi AC, Maverakis E, Tsoi LC, Gudjonsson JE. Novel insights into atopic dermatitis. J Allergy Clin Immunol. 2023;151(5):1145–1154. doi:10.1016/j.jaci.2022.10.023
Cevikbas F, Steinhoff M. IL-33: a novel danger signal system in atopic dermatitis. J Invest Dermatol. 2012;132(5):1326–1329. doi:10.1038/jid.2012.66
Savva M, Papadopoulos NG, Gregoriou S, et al. Recent advancements in the atopic dermatitis mechanism. Front Biosci. 2024;29(2):84. doi:10.31083/j.fbl2902084
Tsakok T, Woolf R, Smith CH, Weidinger S, Flohr C. Atopic dermatitis: the skin barrier and beyond. Br J Dermatol. 2019;180(3):464–474. doi:10.1111/bjd.16934
Tominaga M, Takamori K. Peripheral itch sensitization in atopic dermatitis. Allergol Int. 2022;71(3):265–277. doi:10.1016/j.alit.2022.04.003
Ständer S, Luger T, Kim B, et al. Cutaneous components leading to pruritus, pain, and neurosensitivity in atopic dermatitis: a narrative review. Dermatol Ther. 2024;14(1):45–57. doi:10.1007/s13555-023-01081-0
Escalante A, Serra-Baldrich E. Pathogenic mechanisms underlying itch in atopic dermatitis: the emerging role of neuroimmune interactions. Eur J Dermatol. 2023;33(4):343–349. doi:10.1684/ejd.2023.4514
Cornelissen C, Marquardt Y, Czaja K. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol. 2012;129(2). doi:10.1016/j.jaci.2011.10.042
Yue C, Zhou H, Wang X, et al. Atopic dermatitis: pathogenesis and therapeutic intervention. MedComm. 2024;5(12):e70029. doi:10.1002/mco2.70029
Armario-Hita J, Galán-Gutiérrez M, Dodero-Anillo J, Carrascosa J, Ruiz-Villaverde R. Updated review on treatment of atopic dermatitis. J Investig Allergol Clin. 2023;33(3):158–167. doi:10.18176/jiaci.0906
Tokura Y, Hayano S. Subtypes of atopic dermatitis: from phenotype to endotype. Allergol Int. 2022;71(1):14–24. doi:10.1016/j.alit.2021.07.003
Belpaire A, van Geel N, Speeckaert R. From IL-17 to IFN-g in inflammatory skin disorders: is transdifferentiation a potential treatment target? Front Immunol. 2022;13. doi:10.3389/fimmu.2022.932265
Mesas‐Fernández A, Bodner E, Hilke FJ, Meier K, Ghoreschi K, Solimani F. Interleukin‐21 in autoimmune and inflammatory skin diseases. Eur J Immunol. 2023;53(4):2250075. doi:10.1002/eji.202250075
Tsai YC, Tsai TF. Overlapping features of psoriasis and atopic dermatitis: from genetics to immunopathogenesis to phenotypes. IJMS. 2022;23(10):5518. doi:10.3390/ijms23105518
Al-Janabi A, Martin P, Simpson C, et al. Blood single-cell transcriptomic and proteomic signatures of paradoxical eczema in patients with psoriasis treated with biologics. J Invest Dermatol. 2025;145(10):2535–2548. doi:10.1016/j.jid.2025.02.153
Kanoh H, Ishitsuka A, Fujine E, et al. IFN- γ reduces epidermal barrier function by affecting fatty acid composition of ceramide in a mouse atopic dermatitis model. J Immunol Res. 2019;2019:1–10. doi:10.1155/2019/3030268
Agnello D, Lankford CSR, Bream J, et al. Cytokines and transcription factors that regulate t helper cell differentiation: new players and new insights. J Clin Immunol. 2003;23(3):147–161. doi:10.1023/A:1023381027062
Finotto S, Glimcher L. T cell directives for transcriptional regulation in asthma. Springer Semin Immunopathol. 2004;25(3–4):281–294. doi:10.1007/s00281-003-0143-1
Lee JW, Wu Q, Jang YP, Choung SY. Topical glucose induces claudin-1 and filaggrin expression in a mouse model of atopic dermatitis and in keratinocyte culture, exerting anti-inflammatory effects by repairing skin barrier function. Acta Derm Venerol. 2018;98(1):19–25. doi:10.2340/00015555-2807
Choi JK, Kim SH. Inhibitory effect of galangin on atopic dermatitis-like skin lesions. Food Chem Toxicol. 2014;68:135–141. doi:10.1016/j.fct.2014.03.021
Krupka-Olek M, Bozek A, Drewienkowska M, Dryjka K, Medrala A. Immunological differences between atopic dermatitis, psoriasis, and their combination in adult patients. Allergologia et Immunopathologia. 2022;50(4):143–146. doi:10.15586/aei.v50i4.557
Ylikoski E, Lund R, Kyläniemi M, et al. IL-12 up-regulates T-bet independently of IFN-c in human CD4+ T cells. Eur J Immunol. 2005;35(11):3297–3306. doi:10.1002/eji.200526101
Bullens DMA, Kasran A, Thielemans K, Bakkus M, Ceuppens JL. CD40L‐induced IL-12 production is further enhanced by the Th2 cytokines IL-4 and IL-13. Scand J Immunol. 2001;53(5):455–463. doi:10.1046/j.1365-3083.2001.00900.x
Dieu-Nosjean MC, Massacrier C, Vanbervliet B, Fridman WH, Caux C. IL-10 induces CCR6 expression during langerhans cell development while IL-4 and IFN-γ suppress it. J Immunol. 2001;167(10):5594–5602. doi:10.4049/jimmunol.167.10.5594
Hatano Y, Elias PM. “Outside-to-inside”, “inside-to-outside”, and “intrinsic” endogenous pathogenic mechanisms in atopic dermatitis: keratinocytes as the key functional cells involved in both permeability barrier dysfunction and immunological alterations. Front Immunol. 2023;14. doi:10.3389/fimmu.2023.1239251
Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5–14. doi:10.1111/cea.13491
Furue M. Regulation of skin barrier function via competition between AHR axis versus IL-13/IL-4‒JAK‒STAT6/STAT3 axis: pathogenic and therapeutic implications in atopic dermatitis. JCM. 2020;9(11):3741. doi:10.3390/jcm9113741
Dardalhon V, Awasthi A, Kwon H, et al. Interleukin 4 inhibits TGF-β-induced-Foxp3+T cells and generates, in combination with TGF-β, Foxp3− effector T cells that produce interleukins 9 and 10. 2010.
Niehues T, Hardenberg SV, Velleuer E. Rapid identification of primary atopic disorders (PAD) by a clinical landmarkguided, upfront use of genomic sequencing. ALS. 2024;8(01):304–323. doi:10.5414/ALX02520E
Schramm G, Suwandi A, Galeev A, et al. Schistosome eggs impair protective Th1/Th17 immune responses against salmonella infection. Front Immunol. 2018;9:2614. doi:10.3389/fimmu.2018.02614
He R, Kim HY, Yoon J, et al. Exaggerated IL-17 response to epicutaneous sensitization mediates airway inflammation in the absence of IL-4 and IL-13. J Allergy Clin Immunol. 2009;124(4):761–770.e1. doi:10.1016/j.jaci.2009.07.040
Ghoreschi K, Laurence A, Yang XP, Hirahara K, O’Shea JJ. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trend Immunol. 2011;32(9):395–401. doi:10.1016/j.it.2011.06.007
Guttman-Yassky E, Suárez-Fariñas M, Chiricozzi A, et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol. 2009;124(6):1235–1244.e58. doi:10.1016/j.jaci.2009.09.031
Harper EG, Guo C, Rizzo H, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129(9):2175–2183. doi:10.1038/jid.2009.65
Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203(10):2271–2279. doi:10.1084/jem.20061308
Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-γ- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol. 2000;115(1):81–87. doi:10.1046/j.1523-1747.2000.00041.x
Johnson-Huang LM, McNutt NS, Krueger JG, Lowes MA. Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol. 2009;29(3):247–256. doi:10.1007/s10875-009-9278-8
Cabanillas B, Novak N. Atopic dermatitis and filaggrin. Curr Opin Immunol. 2016;42:1–8. doi:10.1016/j.coi.2016.05.002
Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009;124(3):R7–12. doi:10.1016/j.jaci.2009.07.012
Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol. 2008;181(10):7420–7427. doi:10.4049/jimmunol.181.10.7420
Albanesi C, Madonna S, Gisondi P, Girolomoni G. The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis. Front Immunol. 2018;9:1549. doi:10.3389/fimmu.2018.01549
Noda S, Suárez-Fariñas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136(5):1254–1264. doi:10.1016/j.jaci.2015.08.015
Kim BS, Siracusa MC, Saenz SA, et al. TSLP elicits IL-33–independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med. 2013;5(170). doi:10.1126/scitranslmed.3005374
Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3(7):673–680. doi:10.1038/ni805
Divekar R, Kita H. Recent advances in epithelium-derived cytokines (IL-33, IL-25 and TSLP) and allergic inflammation. Curr Opin Allergy Clin Immunol. 2015;15(1):98–103. doi:10.1097/ACI.0000000000000133
Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol. 2022;158(4):404. doi:10.1001/jamadermatol.2022.0029
O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–328. doi:10.1146/annurev-med-051113-024537
Sano S, Chan KS, DiGiovanni J. Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases. J Dermatological Sci. 2008;50(1):1–14. doi:10.1016/j.jdermsci.2007.05.016
Iznardo H, Puig L. IL-1 family cytokines in inflammatory dermatoses: pathogenetic role and potential therapeutic implications. IJMS. 2022;23(16):9479. doi:10.3390/ijms23169479
Egeberg A, Skov L, Gislason G, Thyssen J, Mallbris L. Incidence and prevalence of psoriasis in Denmark. Acta Derm Venerol. 2017;97(7):808–812. doi:10.2340/00015555-2672
Christophers E, Henseler T. Contrasting disease patterns in psoriasis and atopic dermatitis. Arch Dermatol Res. 1987;279(S1):S48–S51. doi:10.1007/BF00585919
Eyerich S, Onken AT, Weidinger S, et al. mutual antagonism of T cells causing psoriasis and atopic eczema. N Engl J Med. 2011;365(3):231–238. doi:10.1056/NEJMoa1104200
Zhao D, Wu S, Wang Y, Zheng H, Zhu M. Association between allergic diseases and both psoriasis and psoriatic arthritis: a bidirectional 2-sample mendelian randomization study. Arch Dermatol Res. 2024;316(5):181. doi:10.1007/s00403-024-02978-2
Baurecht H, Hotze M, Brand S, et al. Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms. Am J Hum Genet. 2015;96(1):104–120. doi:10.
